Report cover image

Global Therapeutic Vaccines Market By Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, Others) , By Technology (Allogeneic Vaccine, Autologous Vaccine) : Global Opportunity Analysis and Ind

Publisher Allied Market Research
Published Aug 01, 2024
Length 300 Pages
SKU # ALMR19510167

Description

Global Therapeutic Vaccines Market By Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, Others) , By Technology (Allogeneic Vaccine, Autologous Vaccine) : Global Opportunity Analysis and Industry Forecast, 2024-2033


Therapeutic Vaccines Market Expected to Garner $135.7 Billion by 2033, Growing at a CAGR of 19.1%

The global therapeutic vaccines market is expected to grow primarily due to the growing prevalence of chronic diseases & infectious ailments and technological advancements in vaccine development. The Asia-Pacific region is predicted to witness profitable growth by 2033.
As per the report published by Research Dive, the global therapeutic vaccines market was valued at $26.7 billion in 2023 and is expected to register a revenue of $135.7 billion by 2033 at a CAGR of 19.1% during the forecast period 2024-2033.

Dynamics of the Market

The increasing incidence of diseases such as cancer, HIV, and neurological and autoimmune diseases, and the growing demand for personalized medicine & targeted therapies are expected to make the therapeutic vaccines market a highly profitable one in the forecast period. Besides, the increased funding and initiatives from governments & NGOs and the expanding applications of therapeutic vaccines beyond infectious diseases are other factors predicted to boost the market growth.
However, according to market analysts, high production costs, complex manufacturing processes, and stringent approval requirements might restrain the growth of the market.
Technological advancements, integration of machine learning & artificial intelligence in vaccine design & development, and growing investments in R&D are predicted to offer numerous growth opportunities for the therapeutics vaccines market in the forecast period. Moreover, continued investments by major market players accelerate vaccine development and availability.

Key Players of the Market

The major players of the therapeutic vaccines market include Agenus Inc., Celldex Therapeutic Inc., Argos Therapeutic Inc., Dendreon Pharmaceuticals LLC, Merck & Co. Inc., GSK plc, Novartis AG, Phio Pharmaceuticals Corp., Pfizer, Inc., AstraZeneca, INOVIO Pharmaceuticals, and BioNTech SE.

What the Report Covers

In addition to the details highlighted in this description, the comprehensive final report delves into essential market aspects. These encompass a market overview, SWOT analysis, market dynamics, Porter’s five forces analysis, segmentation (key trends, regional analysis, and forecast analysis), and company profiles (including company overview, product portfolio, operating segments, strategic initiatives, and financial performance).

Key Market Segments

By Product

Autoimmune Disease Vaccines
Neurological Disease Vaccines
Cancer Vaccines
Infectious Disease Vaccines
Others

By Technology

Allogeneic Vaccine
Autologous Vaccine

By Region

North America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
UAE
Rest of LAMEA

Key Market Players

Agenus Inc.
Argos Therapeutics, Inc.
Celldex Therapeutics Inc.
Dendreon Pharmaceuticals LLC
GSK plc.
Merck & Co. Inc.
Novartis AG
Pfizer, Inc.
AstraZeneca
BioNTech SE

Table of Contents

300 Pages
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: THERAPEUTIC VACCINES MARKET, BY PRODUCT
4.1. Market Overview
4.1.1 Market Size and Forecast, By Product
4.2. Autoimmune Disease Vaccines
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Neurological Disease Vaccines
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Cancer Vaccines
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Infectious Disease Vaccines
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
4.6. Others
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, By Region
4.6.3. Market Share Analysis, By Country
CHAPTER 5: THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY
5.1. Market Overview
5.1.1 Market Size and Forecast, By Technology
5.2. Allogeneic Vaccine
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Autologous Vaccine
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: THERAPEUTIC VACCINES MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Product
6.2.3. Market Size and Forecast, By Technology
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Therapeutic Vaccines Market
6.2.5.1. Market Size and Forecast, By Product
6.2.5.2. Market Size and Forecast, By Technology
6.2.6. Canada Therapeutic Vaccines Market
6.2.6.1. Market Size and Forecast, By Product
6.2.6.2. Market Size and Forecast, By Technology
6.2.7. Mexico Therapeutic Vaccines Market
6.2.7.1. Market Size and Forecast, By Product
6.2.7.2. Market Size and Forecast, By Technology
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Product
6.3.3. Market Size and Forecast, By Technology
6.3.4. Market Size and Forecast, By Country
6.3.5. France Therapeutic Vaccines Market
6.3.5.1. Market Size and Forecast, By Product
6.3.5.2. Market Size and Forecast, By Technology
6.3.6. Germany Therapeutic Vaccines Market
6.3.6.1. Market Size and Forecast, By Product
6.3.6.2. Market Size and Forecast, By Technology
6.3.7. Italy Therapeutic Vaccines Market
6.3.7.1. Market Size and Forecast, By Product
6.3.7.2. Market Size and Forecast, By Technology
6.3.8. Spain Therapeutic Vaccines Market
6.3.8.1. Market Size and Forecast, By Product
6.3.8.2. Market Size and Forecast, By Technology
6.3.9. UK Therapeutic Vaccines Market
6.3.9.1. Market Size and Forecast, By Product
6.3.9.2. Market Size and Forecast, By Technology
6.3.10. Rest Of Europe Therapeutic Vaccines Market
6.3.10.1. Market Size and Forecast, By Product
6.3.10.2. Market Size and Forecast, By Technology
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Product
6.4.3. Market Size and Forecast, By Technology
6.4.4. Market Size and Forecast, By Country
6.4.5. China Therapeutic Vaccines Market
6.4.5.1. Market Size and Forecast, By Product
6.4.5.2. Market Size and Forecast, By Technology
6.4.6. Japan Therapeutic Vaccines Market
6.4.6.1. Market Size and Forecast, By Product
6.4.6.2. Market Size and Forecast, By Technology
6.4.7. India Therapeutic Vaccines Market
6.4.7.1. Market Size and Forecast, By Product
6.4.7.2. Market Size and Forecast, By Technology
6.4.8. South Korea Therapeutic Vaccines Market
6.4.8.1. Market Size and Forecast, By Product
6.4.8.2. Market Size and Forecast, By Technology
6.4.9. Australia Therapeutic Vaccines Market
6.4.9.1. Market Size and Forecast, By Product
6.4.9.2. Market Size and Forecast, By Technology
6.4.10. Rest of Asia-Pacific Therapeutic Vaccines Market
6.4.10.1. Market Size and Forecast, By Product
6.4.10.2. Market Size and Forecast, By Technology
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Product
6.5.3. Market Size and Forecast, By Technology
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Therapeutic Vaccines Market
6.5.5.1. Market Size and Forecast, By Product
6.5.5.2. Market Size and Forecast, By Technology
6.5.6. South Africa Therapeutic Vaccines Market
6.5.6.1. Market Size and Forecast, By Product
6.5.6.2. Market Size and Forecast, By Technology
6.5.7. Saudi Arabia Therapeutic Vaccines Market
6.5.7.1. Market Size and Forecast, By Product
6.5.7.2. Market Size and Forecast, By Technology
6.5.8. UAE Therapeutic Vaccines Market
6.5.8.1. Market Size and Forecast, By Product
6.5.8.2. Market Size and Forecast, By Technology
6.5.9. Rest of LAMEA Therapeutic Vaccines Market
6.5.9.1. Market Size and Forecast, By Product
6.5.9.2. Market Size and Forecast, By Technology
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Agenus Inc.
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Argos Therapeutics, Inc.
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Celldex Therapeutics Inc.
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Dendreon Pharmaceuticals LLC
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. GSK Plc.
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Merck And Co. Inc.
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Novartis AG
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Pfizer, Inc.
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. AstraZeneca
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. BioNTech SE
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. GLOBAL THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 2. THERAPEUTIC VACCINES MARKET FOR AUTOIMMUNE DISEASE VACCINES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 3. THERAPEUTIC VACCINES MARKET FOR NEUROLOGICAL DISEASE VACCINES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 4. THERAPEUTIC VACCINES MARKET FOR CANCER VACCINES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 5. THERAPEUTIC VACCINES MARKET FOR INFECTIOUS DISEASE VACCINES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 6. THERAPEUTIC VACCINES MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 7. GLOBAL THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 8. THERAPEUTIC VACCINES MARKET FOR ALLOGENEIC VACCINE, BY REGION, 2024 - 2033 ($MILLION)
TABLE 9. THERAPEUTIC VACCINES MARKET FOR AUTOLOGOUS VACCINE, BY REGION, 2024 - 2033 ($MILLION)
TABLE 10. THERAPEUTIC VACCINES MARKET, BY REGION, 2024 - 2033 ($MILLION)
TABLE 11. NORTH AMERICA THERAPEUTIC VACCINES MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 12. NORTH AMERICA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 13. NORTH AMERICA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 14. U.S. THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 15. U.S. THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 16. CANADA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 17. CANADA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 18. MEXICO THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 19. MEXICO THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 20. EUROPE THERAPEUTIC VACCINES MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 21. EUROPE THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 22. EUROPE THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 23. FRANCE THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 24. FRANCE THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 25. GERMANY THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 26. GERMANY THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 27. ITALY THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 28. ITALY THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 29. SPAIN THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 30. SPAIN THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 31. UK THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 32. UK THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 33. REST OF EUROPE THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 34. REST OF EUROPE THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 35. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 36. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 37. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 38. CHINA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 39. CHINA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 40. JAPAN THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 41. JAPAN THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 42. INDIA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 43. INDIA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 44. SOUTH KOREA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 45. SOUTH KOREA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 46. AUSTRALIA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 47. AUSTRALIA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 50. LAMEA THERAPEUTIC VACCINES MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 51. LAMEA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 52. LAMEA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 53. BRAZIL THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 54. BRAZIL THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 55. SOUTH AFRICA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 56. SOUTH AFRICA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 57. SAUDI ARABIA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 58. SAUDI ARABIA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 59. UAE THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 60. UAE THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 61. REST OF LAMEA THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2024 - 2033 ($MILLION)
TABLE 62. REST OF LAMEA THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2024 - 2033 ($MILLION)
TABLE 63. AGENUS INC.: KEY EXECUTIVES
TABLE 64. AGENUS INC.: COMPANY SNAPSHOT
TABLE 65. AGENUS INC.: OPERATING SEGMENTS
TABLE 66. AGENUS INC.: PRODUCT PORTFOLIO
TABLE 67. AGENUS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 68. ARGOS THERAPEUTICS, INC.: KEY EXECUTIVES
TABLE 69. ARGOS THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 70. ARGOS THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 71. ARGOS THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 72. ARGOS THERAPEUTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 73. CELLDEX THERAPEUTICS INC.: KEY EXECUTIVES
TABLE 74. CELLDEX THERAPEUTICS INC.: COMPANY SNAPSHOT
TABLE 75. CELLDEX THERAPEUTICS INC.: OPERATING SEGMENTS
TABLE 76. CELLDEX THERAPEUTICS INC.: PRODUCT PORTFOLIO
TABLE 77. CELLDEX THERAPEUTICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 78. DENDREON PHARMACEUTICALS LLC: KEY EXECUTIVES
TABLE 79. DENDREON PHARMACEUTICALS LLC: COMPANY SNAPSHOT
TABLE 80. DENDREON PHARMACEUTICALS LLC: OPERATING SEGMENTS
TABLE 81. DENDREON PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 82. DENDREON PHARMACEUTICALS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 83. GSK PLC.: KEY EXECUTIVES
TABLE 84. GSK PLC.: COMPANY SNAPSHOT
TABLE 85. GSK PLC.: OPERATING SEGMENTS
TABLE 86. GSK PLC.: PRODUCT PORTFOLIO
TABLE 87. GSK PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 88. MERCK AND CO. INC.: KEY EXECUTIVES
TABLE 89. MERCK AND CO. INC.: COMPANY SNAPSHOT
TABLE 90. MERCK AND CO. INC.: OPERATING SEGMENTS
TABLE 91. MERCK AND CO. INC.: PRODUCT PORTFOLIO
TABLE 92. MERCK AND CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 93. NOVARTIS AG: KEY EXECUTIVES
TABLE 94. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 95. NOVARTIS AG: OPERATING SEGMENTS
TABLE 96. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 97. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 98. PFIZER, INC.: KEY EXECUTIVES
TABLE 99. PFIZER, INC.: COMPANY SNAPSHOT
TABLE 100. PFIZER, INC.: OPERATING SEGMENTS
TABLE 101. PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 102. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 103. ASTRAZENECA: KEY EXECUTIVES
TABLE 104. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 105. ASTRAZENECA: OPERATING SEGMENTS
TABLE 106. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 107. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 108. BIONTECH SE: KEY EXECUTIVES
TABLE 109. BIONTECH SE: COMPANY SNAPSHOT
TABLE 110. BIONTECH SE: OPERATING SEGMENTS
TABLE 111. BIONTECH SE: PRODUCT PORTFOLIO
TABLE 112. BIONTECH SE: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL THERAPEUTIC VACCINES MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF THERAPEUTIC VACCINES MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN THERAPEUTIC VACCINES MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALTHERAPEUTIC VACCINES MARKET
FIGURE 10. GLOBAL THERAPEUTIC VACCINES MARKET SEGMENTATION, BY PRODUCT
FIGURE 11. THERAPEUTIC VACCINES MARKET FOR AUTOIMMUNE DISEASE VACCINES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 12. THERAPEUTIC VACCINES MARKET FOR NEUROLOGICAL DISEASE VACCINES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 13. THERAPEUTIC VACCINES MARKET FOR CANCER VACCINES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 14. THERAPEUTIC VACCINES MARKET FOR INFECTIOUS DISEASE VACCINES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 15. THERAPEUTIC VACCINES MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 16. GLOBAL THERAPEUTIC VACCINES MARKET SEGMENTATION, BY TECHNOLOGY
FIGURE 17. THERAPEUTIC VACCINES MARKET FOR ALLOGENEIC VACCINE, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 18. THERAPEUTIC VACCINES MARKET FOR AUTOLOGOUS VACCINE, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 23. COMPETITIVE DASHBOARD
FIGURE 24. COMPETITIVE HEATMAP: THERAPEUTIC VACCINES MARKET
FIGURE 25. TOP PLAYER POSITIONING, 2023
FIGURE 26. AGENUS INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 27. AGENUS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 28. AGENUS INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 29. ARGOS THERAPEUTICS, INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 30. ARGOS THERAPEUTICS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 31. ARGOS THERAPEUTICS, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 32. CELLDEX THERAPEUTICS INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 33. CELLDEX THERAPEUTICS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 34. CELLDEX THERAPEUTICS INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 35. DENDREON PHARMACEUTICALS LLC: NET SALES, 2021-2023 ($MILLION)
FIGURE 36. DENDREON PHARMACEUTICALS LLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. DENDREON PHARMACEUTICALS LLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 38. GSK PLC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 39. GSK PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. GSK PLC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 41. MERCK AND CO. INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 42. MERCK AND CO. INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. MERCK AND CO. INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 44. NOVARTIS AG: NET SALES, 2021-2023 ($MILLION)
FIGURE 45. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 47. PFIZER, INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 48. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. PFIZER, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 50. ASTRAZENECA: NET SALES, 2021-2023 ($MILLION)
FIGURE 51. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 52. ASTRAZENECA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 53. BIONTECH SE: NET SALES, 2021-2023 ($MILLION)
FIGURE 54. BIONTECH SE: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 55. BIONTECH SE: REVENUE SHARE, BY REGION, 2023 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us